These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38236528)

  • 1. Urine Mast Cell Mediators in the Evaluation and Diagnosis of Mast Cell Activation Syndrome.
    Voelker D; Pongdee T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):33-38. PubMed ID: 38236528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
    Butterfield JH; Ravi A; Pongdee T
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
    Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH; Weiler CR
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
    Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Rubin P; Cohn J; White MV; Igarashi Y; Kaliner MA; Drazen JM
    J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):1046-56. PubMed ID: 7798537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.
    Ono E; Taniguchi M; Mita H; Fukutomi Y; Higashi N; Miyazaki E; Kumamoto T; Akiyama K
    Clin Exp Allergy; 2009 Jan; 39(1):72-80. PubMed ID: 19128354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the role of PGD2 metabolites as markers of mast cell activation in asthma.
    O'Sullivan S
    Acta Physiol Scand Suppl; 1999 Apr; 644():1-74. PubMed ID: 10352758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma.
    Mita H; Endoh S; Kudoh M; Kawagishi Y; Kobayashi M; Taniguchi M; Akiyama K
    Allergy; 2001 Nov; 56(11):1061-7. PubMed ID: 11703219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell activation syndrome: a review.
    Frieri M; Patel R; Celestin J
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):27-32. PubMed ID: 23179866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mast cell mediators in systemic mastocytosis and hereditary α-tryptasemia.
    Giannetti MP; Godwin G; Weller E; Butterfield JH; Castells M
    J Allergy Clin Immunol; 2022 Nov; 150(5):1225-1227. PubMed ID: 35550148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of mast cell activation and leukotriene release after mannitol inhalation.
    Brannan JD; Gulliksson M; Anderson SD; Chew N; Kumlin M
    Eur Respir J; 2003 Sep; 22(3):491-6. PubMed ID: 14516140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma.
    Bochenek G; Nizankowska E; Gielicz A; Swierczyńska M; Szczeklik A
    Thorax; 2004 Jun; 59(6):459-64. PubMed ID: 15170023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
    Castells M; Butterfield J
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
    Cahill KN; Wu P; Milne GL; Amin T; Singer J; Murphy K; Lewis E; Gapko D; Boyce JA; Buchheit KM; Laidlaw TM
    J Allergy Clin Immunol; 2022 Jul; 150(1):170-177.e6. PubMed ID: 35026207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.